share_log

和黃醫藥：自願性公告 - 和黃醫藥宣佈創響生物根據戰略合作協議行使選擇權以取得兩款候選藥物的授權許可

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

香港交易所 ·  Feb 2 03:33
Summary by Moomoo AI
和黃醫藥（HUTCHMED）今日宣布，根據2021年1月11日的戰略合作條款，創響生物已行使選擇權，取得IMG-007和IMG-004兩款候選藥物的全球開發、生產和商業化獨家權益。創響生物將支付約7.5%的普通股股份給和黃醫藥，並有權獲得最高達9,250萬美元的開發里程碑付款和最高1.35億美元的商業銷售里程碑付款，以及商業化後分成。IMG-007目前正在進行全球IIa期臨床試驗，用於治療中度至重度特應性皮炎和斑禿，而IMG-004已完成I期單次劑量遞增研究，是一種針對免疫性疾病的BTK抑制劑。和黃醫藥首席執行官兼首席科學官蘇慰國博士表示，這項合作展示了和黃醫藥候選藥物的潛力，並期待與創響生物合作，為免疫性疾病患者帶來改變。
和黃醫藥（HUTCHMED）今日宣布，根據2021年1月11日的戰略合作條款，創響生物已行使選擇權，取得IMG-007和IMG-004兩款候選藥物的全球開發、生產和商業化獨家權益。創響生物將支付約7.5%的普通股股份給和黃醫藥，並有權獲得最高達9,250萬美元的開發里程碑付款和最高1.35億美元的商業銷售里程碑付款，以及商業化後分成。IMG-007目前正在進行全球IIa期臨床試驗，用於治療中度至重度特應性皮炎和斑禿，而IMG-004已完成I期單次劑量遞增研究，是一種針對免疫性疾病的BTK抑制劑。和黃醫藥首席執行官兼首席科學官蘇慰國博士表示，這項合作展示了和黃醫藥候選藥物的潛力，並期待與創響生物合作，為免疫性疾病患者帶來改變。
HUANG PHARMACEUTICALS (HUTCHMED) ANNOUNCED TODAY THAT UNDER THE TERMS OF A STRATEGIC PARTNERSHIP DATED JANUARY 11, 2021, IMPACT BIOLOGICS HAS EXERCISED AN OPTION TO ACQUIRE EXCLUSIVE RIGHTS IN THE GLOBAL DEVELOPMENT, PRODUCTION AND COMMERCIALIZATION OF IMG-007 AND IMG-004 TWO CANDIDATE DRUGS. Impact Bios will pay approximately 7.5% of common stock to Wong Pharmaceuticals and will be entitled to up to $9,250 million in development milestone payments and up to $1.35 million in commercial sales milestone payments, as well as post-commercialization distributions. IMG-007 is currently undergoing a global Phase IIa clinical trial for the treatment of moderate to severe characteristic dermatitis and alopecia, and IMG-004 has completed a Phase I single-dose incremental study and is a BTK inhibitor for immune diseases. Dr. Su Yuguo, CEO and Chief Scientific Officer of Wong Medicine, said that this collaboration demonstrates the potential of Wong Pharmaceutical's drug candidates and looks forward to working with Impact Biologics to make a difference for patients with immune diseases.
HUANG PHARMACEUTICALS (HUTCHMED) ANNOUNCED TODAY THAT UNDER THE TERMS OF A STRATEGIC PARTNERSHIP DATED JANUARY 11, 2021, IMPACT BIOLOGICS HAS EXERCISED AN OPTION TO ACQUIRE EXCLUSIVE RIGHTS IN THE GLOBAL DEVELOPMENT, PRODUCTION AND COMMERCIALIZATION OF IMG-007 AND IMG-004 TWO CANDIDATE DRUGS. Impact Bios will pay approximately 7.5% of common stock to Wong Pharmaceuticals and will be entitled to up to $9,250 million in development milestone payments and up to $1.35 million in commercial sales milestone payments, as well as post-commercialization distributions. IMG-007 is currently undergoing a global Phase IIa clinical trial for the treatment of moderate to severe characteristic dermatitis and alopecia, and IMG-004 has completed a Phase I single-dose incremental study and is a BTK inhibitor for immune diseases. Dr. Su Yuguo, CEO and Chief Scientific Officer of Wong Medicine, said that this collaboration demonstrates the potential of Wong Pharmaceutical's drug candidates and looks forward to working with Impact Biologics to make a difference for patients with immune diseases.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more